Like many other cardiac monitoring companies, Seattle-Based Bardy Diagnostics is using its technology to remotely monitor the QT intervals of COVID-19 patients during the pandemic. The company is reporting that Seattle-area hospitals are using its Carnation ambulatory monitor (CAM) patch to measure QT segments in patients who have been prescribed hydroxychloroquine.
The patch will also be used on discharged patients and outpatients still taking hydroxychloroquine. The company is also offering mail-to-patient services for individuals to apply the CAM patch at home.
Unlike many companies who have changed direction in order to support the Pandemic, Bardy Diagnostics already has significant IP in cardiac monitoring, and this week was issued its fourth patent in the AI-biotech sector (all since April 2019).
Bardy Diagnostics received FDA 510(k) clearance for the 14-Day version of the CAM last September, expanding a product line that previously contained 2-Day and 7-Day versions. The 14-Day version was officially launched this past January.
